Loading...
•
Dec 31, 2023
Compass Q4 2023 Earnings Report
Reported full year 2023 financial results and provided business update.
Key Takeaways
Compass Therapeutics reported a net loss of $42.5 million for the year ended December 31, 2023, and ended the year with $152.5 million in cash and marketable securities, extending the cash runway into mid-2026. The company is focused on clinical development of CTX-009 and expects to report top-line data from Phase 2 trials by mid and end of the year.
Strategically shifted focus toward clinical development of CTX-009.
Expects to report top-line data from Stage 1 of the Phase 2 COMPANION-003 trial by mid-year.
Expects to report top-line data from Phase 2/3 COMPANION-002 trial by the end of the year.
Ended the year with $152.5 million, extending cash runway into the middle of 2026.